C3 GLOMERULONEPHRITIS
Clinical trials for C3 GLOMERULONEPHRITIS explained in plain language.
Never miss a new study
Get alerted when new C3 GLOMERULONEPHRITIS trials appear
Sign up with your email to follow new studies for C3 GLOMERULONEPHRITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for controlling rare kidney disorders
Disease control OngoingThis study tests the long-term safety and effectiveness of pegcetacoplan in 100 people with two rare kidney diseases, C3 glomerulopathy and IC-MPGN. Participants previously completed a one-year trial and saw benefit from the drug. The goal is to see if pegcetacoplan can keep redu…
Matched conditions: C3 GLOMERULONEPHRITIS
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for rare kidney disease patients: early access to pegcetacoplan
Disease control APPROVED_FOR_MARKETINGThis program provides early access to pegcetacoplan for people aged 12 and older with C3 glomerulopathy or primary IC-MPGN, rare kidney diseases that can lead to kidney failure. Participants must have active disease with significant protein in their urine. The goal is to offer a …
Matched conditions: C3 GLOMERULONEPHRITIS
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC